Citations 2
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Benson, Al B. , D’Angelica, Michael I. , Ahmed, Aijaz, Akce, Mehmet , Anaya, Daniel A. , Are, Chandrakanth , Aye, Lydia, Baker, Marshall S., Binder, David C. , Burgoyne, Adam M. , Castellanos, Jason , Cloyd, Jordan M. , Franses, Joseph W. , Harris, William P., Iyer, Renuka , Jennings, Lawrence J. , Kelley, Robin Kate , Khan, Sajid , Palta, Manisha , Sahai, Vaibhav , Stein, Stacey , Stephans, Kevin L. , Thanikachalam, Kannan , Yano, Motoyo , Yopp, Adam C. , Zhao, Ken, Schonfeld, Ryan, Hochstetler, Cindy, Sahai, Vaibhav , Abrams, Thomas A. , Anders, Robert A. , Bachini, Melinda , Brown, Daniel B. , Cullinan, Darren R. , Glazer, Evan S. , Levine, Matthew H , Melstrom, Laleh , Raman, Steven S. , Ronnekleiv-Kelly, Sean M , Turk, Anita , Vauthey, Jean‐Nicolas , Venook, Alan P. , Zhao, Ken
Journal of the National Comprehensive Cancer Network | September 10, 2025 | Volume: 23 | Issue: 9 | Pages: 403-418
The NCCN Guidelines for Biliary Tract Cancers (BTCs) provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts is convened at least once annually to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. This manuscript focuses on the adjuvant chemotherapy and chemoradiation treatment options for BTCs as well as the systemic treatment recommendations for patients with advanced BTCs.
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, Manisha H. , Benson, Al B. , Bergsland, Emily K. , Blaszkowsky, Lawrence S. , Brock, Pamela , Chan, J.K.C., Das, Satya , Dickson, Paxton V. , Fanta, Paul T. , Giordano, Thomas J. , Halperin, Daniel M. , He, Jin , Heaney, Anthony P. , Heslin, Martin J. , Kandeel, Fouad , Kardan, Arash , Khan, Sajid , Kuvshinoff, Boris W. , Miller, Kimberly D. , Reidy‐Lagunes, Diane , Salgado, Sarimar Agosto , Shaheen, Shagufta , Sussman, Craig, Trikalinos, Nikolaos A. , Uboha, N., Vijayvergia, Namrata , Lynn, Beth, Hochstetler, Cindy, Trikalinos, Nikolaos A , Goldner, Whitney Sears , Hálfdánarson, Þorvarður R. , Lieu, Christopher H. , Pillarisetty, Venu Gopal , Soares, Heloisa P. , Soulen, Michael C , Strosberg, Jonathan , Wong, Terence Z.
Journal of the National Comprehensive Cancer Network | August 2, 2021 | Volume: 19 | Issue: 7 | Pages: 839-868
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paragangliomas, and multiple endocrine neoplasia. NETs are generally subclassified by site of origin, stage, and histologic characteristics. Appropriate diagnosis and treatment of NETs often involves collaboration between specialists in multiple disciplines, using specific biochemical, radiologic, and surgical methods. Specialists include pathologists, endocrinologists, radiologists (including nuclear medicine specialists), and medical, radiation, and surgical oncologists. These guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine and adrenal tumors and are intended to assist with clinical decision-making. This article is focused on the 2021 NCCN Guidelines principles of genetic risk assessment and counseling and recommendations for well-differentiated grade 3 NETs, poorly differentiated neuroendocrine carcinomas, adrenal tumors, pheochromocytomas, and paragangliomas.